1. Home
  2. HUMA vs JCE Comparison

HUMA vs JCE Comparison

Compare HUMA & JCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HUMA
  • JCE
  • Stock Information
  • Founded
  • HUMA 2004
  • JCE 2007
  • Country
  • HUMA United States
  • JCE United States
  • Employees
  • HUMA N/A
  • JCE N/A
  • Industry
  • HUMA Biotechnology: Pharmaceutical Preparations
  • JCE Trusts Except Educational Religious and Charitable
  • Sector
  • HUMA Health Care
  • JCE Finance
  • Exchange
  • HUMA Nasdaq
  • JCE Nasdaq
  • Market Cap
  • HUMA 250.2M
  • JCE 262.6M
  • IPO Year
  • HUMA N/A
  • JCE N/A
  • Fundamental
  • Price
  • HUMA $1.51
  • JCE $15.72
  • Analyst Decision
  • HUMA Strong Buy
  • JCE
  • Analyst Count
  • HUMA 8
  • JCE 0
  • Target Price
  • HUMA $10.88
  • JCE N/A
  • AVG Volume (30 Days)
  • HUMA 5.9M
  • JCE 49.7K
  • Earning Date
  • HUMA 08-11-2025
  • JCE 01-01-0001
  • Dividend Yield
  • HUMA N/A
  • JCE 9.26%
  • EPS Growth
  • HUMA N/A
  • JCE N/A
  • EPS
  • HUMA N/A
  • JCE N/A
  • Revenue
  • HUMA $818,000.00
  • JCE N/A
  • Revenue This Year
  • HUMA N/A
  • JCE N/A
  • Revenue Next Year
  • HUMA $949.92
  • JCE N/A
  • P/E Ratio
  • HUMA N/A
  • JCE N/A
  • Revenue Growth
  • HUMA N/A
  • JCE N/A
  • 52 Week Low
  • HUMA $1.15
  • JCE $11.64
  • 52 Week High
  • HUMA $6.77
  • JCE $14.28
  • Technical
  • Relative Strength Index (RSI)
  • HUMA 36.87
  • JCE 60.84
  • Support Level
  • HUMA $1.43
  • JCE $15.36
  • Resistance Level
  • HUMA $1.67
  • JCE $15.84
  • Average True Range (ATR)
  • HUMA 0.15
  • JCE 0.15
  • MACD
  • HUMA -0.01
  • JCE 0.01
  • Stochastic Oscillator
  • HUMA 23.32
  • JCE 73.47

About HUMA Humacyte Inc.

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

About JCE Nuveen Core Equity Alpha Fund of Beneficial Interest

Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to provide an attractive level of total return, through long-term capital appreciation and through income and gains. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities.

Share on Social Networks: